Medtronic Starts Next-Gen Drug-Eluting Stent Trials
This article was originally published in The Gray Sheet
The company is initially targeting very small vessels in a new pivotal study for its Resolute Onyx zotarolimus-eluting stent. Medtronic is separately launching a study of its novel "drug-filled" stent platform.
You may also be interested in...
One of the most controversial, and potentially impactful, questions in medical device development today is how to better prevent late events, especially late stent-thrombosis, in coronary stent patients. The two leading answers to this question are a completely bioresorbable drug-eluting stent and a metal drug-eluting stent with a bioresorbable polymer, but there may be even more ideas on the horizon. One of the leading experts in the field and a cardiologist with experience with most of these new technologies, Robert Byrne of Deutsches Herzzentrum in Munich, recently talked to Medtech Insight about the questions that still need to be answered in this field and how it can move forward.
The first company to enter the drug-eluting stent market will now be the first to depart.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.